Skip to main content


Cheryl Ho, MD, FRCP(C)

Cheryl Ho, MD, FRCPC

Clinical Associate Professor
University of British Columbia
Medical Oncologist
British Columbia Cancer
Vancouver, BC

Cheryl Ho, MD is a medical oncologist at BC Cancer and Clinical Associate Professor at the University of British Columbia. Her clinical practice focuses on thoracic and head & neck malignancies. Dr. Ho evaluates the impact of therapies proven in clinical trials in the real world through population-based analysis. Her current focus is on developing a learning health care system with a real-world data evidence-generation framework to inform healthcare decision-makers.

Barbara Melosky, MD, FRCP(C)

Professor of Medicine, UBC
Medical Oncologist, BC Cancer
Vancouver, BC

Dr. Melosky is a Professor of Medicine at the University of British Columbia and a Medical Oncologist in Vancouver at BC Cancer. She graduated from medical school at the University of Manitoba and did a residency in internal medicine and an oncology fellowship at the University of British Columbia. Dr. Melosky specializes in the field of thoracic malignancy. She sits on the Executive Lung Site Committee for CCTG Canadian Clinical Trials Group.

Her main focus of clinical trials is on EGFR inhibitors; she is published in this area and is considered a national and international expert. Dr. Melosky has chaired the Canadian Lung Cancer Conference for the last 12 years, which is attended by over 350 participants. She chairs and organized the multi-disciplinary Lung Cancer Journal Club three times yearly. She is chair and created the British Columbia Lung Cancer Biobank.

She is also the chairperson of the Colorectal Screening Program of British Columbia and has a special interest in EGFR receptors and management of side effects.

Randeep Sangha, MD, FRCPC

Associate Professor, University of Alberta
Medical Oncologist, Cross Cancer Institute
Director, Clinical Trials Unit, Cross Cancer Institute
Provincial Lead, Alberta Lung Cancer Program
Edmonton, AB

Randeep Sangha, MD, is an Associate Professor at the University of Alberta and a Medical Oncologist at the Cross Cancer Institute in Edmonton, Alberta, Canada.

Dr. Sangha obtained his medical degree from the University of Alberta Faculty of Medicine, where he also completed his his residency in Internal Medicine and Medical Oncology. He then pursued a post-training research fellowship at the University of California, Davis Comprehensive Cancer Center, focusing on thoracic malignancies.

Dr. Sangha is the Director of the Clinical Trials Unit at the Cross Cancer Institute. He also has been the Provincial Lead for the Alberta Lung Cancer Program. His clinical and research interests include treatment of thoracic and hematologic malignancies, as well as developmental and molecular therapeutics.

Devin Schellenberg, MD, FRCS(C)

Clinical Associate Professor – UBC
Department Head, Radiation Oncology
BC Cancer – Surrey Centre

Dr. Devin Schellenberg completed medical school and Residency at the University of BC and University of Toronto.  He went onto a Fellowship at Stanford University and has been the Department Head of Radiation Oncology at the BC Cancer Surrey Centre for the past 4 years. He chairs the Lung Radiation Oncology working group with CCTG and is a founding member of CAPRI (Canadian Pulmonary Radiotherapy Investigators Group).

He has been a leader in BC Cancer’s Stereotactic Ablative Body Radiotherapy (SABR) programs and his current research efforts focus on how radiation can alter the course of metastatic disease and (outside of cancer) whether radiation is able to treat heart arrhythmias.


Mara B. Antonoff MD, FACS

Associate Professor and Program Director of Education
Department of Thoracic and Cardiovascular Surgery
Division of Surgery
University of Texas
MD Anderson Cancer Center
Houston, TX

Dr. Antonoff completed her undergraduate studies at the University of Pennsylvania and earned her medical degree at the University of Minnesota, where she also completed internship and residency in General Surgery. Dr. Antonoff completed a fellowship in Cardiothoracic Surgery at Washington University in St Louis. She joined MD Anderson in 2014, where she’s currently an Associate Professor of Thoracic and Cardiovascular Surgery and Program Director for Education. She is the Deputy Head of Education for Surgery, as well as the Chair of the GME Committee on Diversity and Disparities. Dr. Antonoff’s research interests include pulmonary metastatic disease, early detection of lung cancer, and local consolidative therapy for stage IV lung cancer. She leads a multi-institutional trial for lung-limited metastatic colorectal cancer, and she is the surgical lead for several trials evaluating the role of local consolidative therapy for metastatic non-small cell lung cancer. She holds several leadership roles in the STS, including chair of the STS Career Development Workforce and its leadership Institute. She currently serves as the Vice President and President-Elect of the WTS. She further holds leadership roles within the AATS, the STSA, the AWS, IASLC, ESTS, and the TSDA, as well as Senior Editorial Board positions for Annals of Thoracic Surgery, Journal of Thoracic and Cardiovascular Surgery, Innovations, CTSNet, and Journal of Thoracic Disease. She is the proud mother of 4 children, aged 5 to 15.

David Baldwin

Honorary Professor of Medicine and Consultant Physician
University of Nottingham
Nottingham, UK

David Baldwin works as a consultant respiratory physician sub-specialising in lung cancer and mesothelioma and interventional procedures. He is Honorary Professor in the School of Medicine at the University of Nottingham. He is Lead Clinician for Lung Cancer, NHSE and Chair of the UK Clinical Expert Group for Lung Cancer and Mesothelioma. He is Advisor to the UK National Screening Committee, DHSC. He has obtained research grants from a variety of charities and NIHR to a total value of over £35M as applicant and co-applicant. His primary research interests are in CT screening and lung cancer epidemiology. He is leading the novel recruitment work package in the 4-in-the-Lung-Run project. He was lead respiratory physician on the UK CT lung cancer screening trial (UKLS). He has published over 250 papers, including three influential guidelines. He has held the positions of Honorary Secretary of the British Thoracic Society, Clinical Lead on the NICE Lung Cancer Guideline Development Group, Chair of the Quality Standards Group on Lung Cancer, Clinical Director of the East Midlands Cancer Alliance and Chair of the Screening Prevention and Early Diagnosis Group for the National Cancer Research Institute.

Sarah Dewell, PhD, MSc., RN (she/her)

Assistant Professor, School of Nursing
Thompson Rivers University
Kamloops, BC

Sarah Dewell is an Assistant Professor in the School of Nursing at Thompson Rivers University. Sarah’s research explores the development of precision health through scholarship focused on nursing education, research, and practice with a focus on foundational genomic knowledge for all nurses. Sarah completed a BSc in Cell Biology and Genetics and a Masters in Medical Genetics at the University of British Columbia and a BN and a PhD in Nursing at the University of Calgary. Sarah is a member of the steering committees for the Global Genomics Nursing Alliance (G2NA) and the Canadian Nursing & Genomics initiative. She is also a member of the International Society of Nurses in Genetics (ISONG) and the Nursing Genomics Project Group of the National Human Genome Research Institute’s Inter-Society Coordinating Committee for Practitioner Education in Genomics (ISCC-PEG).

Bertrand Routy MD, PhD

Associate professor of Hemato-Oncology, University of Montreal
Scientific Director of the CHUM Microbiome Centre
University of Montreal Research Centre
Montreal, QC

Dr. Bertrand Routy MD, PhD is a clinician-scientist and associate professor in the department of hemato-oncology at the CHUM (University of Montreal). Upon his recruitment to the CRCHUM in 2018 after completing his PhD with Pr. Laurence Zitvogel, Dr. Routy quickly established himself as the scientific director of the CHUM Microbiome Centre where he began his work to develop novel microbiome-based therapeutics in oncology.

His work contributed to the discovery of the gut microbiome as a novel prognostic biomarker for immune checkpoint inhibitors (ICI) in various cancers. He characterized the deleterious impact of antibiotic-related gut dysbiosis on ICI outcomes, which led to pivotal changes in clinical oncology practice. Moreover, he demonstrated that modulation of the microbiome by fecal microbiota transplantation, probiotics, and prebiotic supplementation had the potential to circumvent ICI resistance. His team currently leads several microbiota- centered trials in oncology ranging from phase I to phase II trials, with the aim of decreasing primary ICI resistance.

Dr. Routy is internationally recognized as a leader in the microbiome field with more than 15,600 citations including publications in Science, Nature Medicine and Annals of oncology, and h-index of 42. Moreover, his unending commitment to improving immunotherapy responses in cancer patients has led to several awards from prestigious societies, including the FRQS 2023 Junior 2 ranked #1, the Prix de la Relève Scientifique du Québec in 2022 and the 2021 Gairdner Foundation award.

Florence Wu, MD-PhD

PGY5 Resident, Medical Oncology
UBC & BC Cancer Vancouver Centre

Florence Wu is a PGY5 Medical Oncology resident at the University of British Columbia, where she also did her Internal Medicine residency training. Prior to this, Dr. Wu completed an MD-PhD at the University of Toronto, doing preclinical research on the use of antiangiogenic drugs (VEGF/VEGFR and Angiopoietin/Tie2 pathway-targeting agents) to reduce vascular permeability and inhibit early cancer metastasis. Dr. Wu will be seeking out further opportunities to study the crosstalk between tumor vascular biology and tumor immunology through a clinical and research fellowship in thoracic medical oncology.